Abstract：Objective To investigate the predictive value of peripheral blood lymphocyte subsets and inflammation related indexes in the occurrence of immune checkpoint inhibitor associated pneumonia (CIP) in advanced lung cancer. Methods A retrospective analysis was performed on the clinical data of 77 patients with advanced lung cancer who received PD-1/PD-L1 inhibitor treatment and lymphocyte subsets detection in Qilu Hospital of Shandong University from February 2019 to November 2021. According to the occurrence of CIP, they were divided into CIP group (11 cases) and non-CIP group (66 cases). The levels of lymphocyte subsets, neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR) and platelet/lymphocyte ratio (PLR) were compared between two groups, and the predictive value of each indicator for CIP occurrence was evaluated by ROC curve. Results During follow-up, CIP occurred in 11 patients, the incidence of 14.3%. The baseline NLR in CIP group was higher than that in non-CIP group, and the difference was statistically significant (P<0.05). However, there were no significant differences in lymphocyte subsets, LMR and PLR between two groups (P>0.05). ROC curve showed that the AUC predicted by NLR for CIP was 0.718 (95%CI: 0.502-0.933), the cut-off value was 4.50, the sensitivity was 75.8%, and the specificity was 72.7%. Conclusion NLR can be used as a predictor of CIP in advanced lung cancer patients before immunotherapy, but lymphocyte subsets, LMR and PLR have no significant correlation with CIP occurrence.
韩利会； 田辉； 杨秋安. 中性粒细胞/淋巴细胞比值对晚期肺癌免疫检查点抑制剂相关性肺炎的预测价值[J]. 中国当代医药, 2022, 29(20): 20-25.
HAN Lihui ； TIAN Hui ； YANG Qiu′an. Predictive value of neutrophil to lymphocyte ratio in immune checkpoint inhibitor-related pneumonitis in lung cancer. 中国当代医药, 2022, 29(20): 20-25.
Yang AP，Liu JP，Tao WQ，et al.The diagnostic and predictive role of NLR，d-NLR and PLR in COVID-19 patients[J].Int Immunopharmacol，2020，84：106504.
[2]
Mok TSK，Wu YL，Kudaba I，et al.Pembrolizumab versus chemotherapy for previously untreated，PD-L1-expressing，locally advanced or metastatic non-small-cell lung cancer（KEYNOTE-042）：a randomised，open-label，controlled，phase 3 trial[J].Lancet，2019，393（10183）：1819-1830.
[4]
Arnaud-Coffin P，Maillet D，Gan HK，et al.A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors[J].Int J Cancer，2019，145（3）：639-648.
[5]
Wang F，Nie J，Wang H，et al.Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia[J].J Infect Dis，2020，221（11）：1762-1769.
[7]
Xie C，Wei B，Li Y.A case-control study on the relationship between the ratio of neutrophils to lymphocytes in malignant tumors and ventilator-associated pneumonia[J].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue，2021，33（2）：165-168.
[12]
Oken MM，Creech RH，Tormey DC，et al.Toxicity and response criteria of the Eastern Cooperative Oncology Group[J].Am J Clin Oncol，1982，5（6）：649-655.
[13]
Amin MB，Greene FL，Edge SB，et al.The Eighth Edition AJCC Cancer Staging Manual：Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J].CA Cancer J Clin，2017，67（2）：93-99.
Suzuki Y，Karayama M，Uto T，et al.Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors：A Multicenter Prospective Study[J].J Thorac Oncol，2020，15（8）：1317-1327.
[18]
Hasegawa S，Ikesue H，Nakao S，et al.Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database[J].Pharmacoepidemiol Drug Saf，2020，29（10）：1279-1294.
Wang DY，Salem JE，Cohen JV，et al.Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors：A Systematic Review and Meta-analysis[J].JAMA Oncol，2018，4（12）：1721-1728.
[21]
Zitvogel L，Tesniere A，Kroemer G.Cancer despite immunosurveillance：immunoselection and immunosubversion[J].Nat Rev Immunol，2006，6（10）：715-727.
[22]
Yu Y，Qian L，Cui J.Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis：A meta-analysis of 7,219 patients[J].Mol Clin Oncol，2017，7（3）：498-506.
[23]
Diem S，Schmid S，Krapf M，et al.Neutrophil-to-Lymphocyte ratio （NLR） and Platelet-to-Lymphocyte ratio （PLR） as prognostic markers in patients with non-small cell lung cancer （NSCLC） treated with nivolumab[J].Lung Cancer，2017，111：176-181.
[24]
Soyano AE，Dholaria B，Marin-Acevedo JA，et al.Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies[J].J Immunother Cancer，2018，6（1）：129.
京公网安备 11010502046607号